Price T Rowe Associates Inc Larimar Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 16,310 shares of LRMR stock, worth $30,499. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,310
Previous 15,452
5.55%
Holding current value
$30,499
Previous $60,000
40.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding LRMR
# of Institutions
109Shares Held
64.5MCall Options Held
93.5KPut Options Held
68K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$39.7 Million1.16% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$11.3 Million0.27% of portfolio
-
Janus Henderson Group PLC London, X05.57MShares$10.4 Million0.01% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.78MShares$8.93 Million5.31% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$6.39 Million6.65% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $80.9M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...